RPHM Reneo Pharmaceuticals, Inc.Stock Price & Overview
$7.050.03 (+0.43%)3:59 PM 10/03/23
NASDAQ | $USD | Pre-Market: $7.30 +0.25 (+3.55%) 8:00 AM
Charts
FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Volume
Prev. Close
Quant Ranking
Analysis
News
Latest Headlines
Ratings Summary
| Now | 6M ago | |
|---|---|---|
SA Analysts | Not CoveredRating: Not Covered | |
Wall Street | Not CoveredRating: Not Covered | |
Quant | Not CoveredRating: Not Covered | |
Ratings Summary
SA Analysts
Wall Street
Quant
| Now | 3M ago | 6M ago | |
|---|---|---|---|
Valuation | -Rating: Not Covered | ||
Growth | -Rating: Not Covered | ||
Profitability | -Rating: Not Covered | ||
Momentum | -Rating: Not Covered | ||
Revisions | -Rating: Not Covered | ||
See RPHM ratings with Premium.
Company Profile
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
Address
- 18575 Jamboree Road
- Suite 275-S
- Irvine, CA, 92612
- United States
Phone Number
858 283 0280
Website